CAS 95635-56-6|Ranolazine dihydrochloride

Introduction：Basic information about CAS 95635-56-6|Ranolazine dihydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Ranolazine dihydrochloride BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Articles1
7. Synonyms

Common Name	Ranolazine dihydrochloride
CAS Number	95635-56-6	Molecular Weight	500.458
Density	/	Boiling Point	624.1ºC at 760 mmHg
Molecular Formula	C₂₄H₃₅Cl₂N₃O₄	Melting Point	222-229.5ºC(lit.)
MSDS	ChineseUSA	Flash Point	/

Names

Name	Ranolazine dihydrochloride
Synonym	More Synonyms

Ranolazine dihydrochloride BiologicalActivity

Description	Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value:Target: sodium-dependent calcium channelRanolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.
Related Catalog	Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Membrane Transporter/Ion Channel >>Calcium ChannelSignaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelResearch Areas >>Cardiovascular Disease
References	[1]. Hawwa N, Menon V. Ranolazine: Clinical Applications and Therapeutic Basis. Am J Cardiovasc Drugs. 2013 Jan 19. [2]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73. [3]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5. [4]. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008 Mar;153(6):1128-32. Epub 2007 Dec 10. [5]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

Description

Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value:Target: sodium-dependent calcium channelRanolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.

Related Catalog

Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Membrane Transporter/Ion Channel >>Calcium ChannelSignaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelResearch Areas >>Cardiovascular Disease

References

[1]. Hawwa N, Menon V. Ranolazine: Clinical Applications and Therapeutic Basis. Am J Cardiovasc Drugs. 2013 Jan 19.

[2]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73.

[3]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.

[4]. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008 Mar;153(6):1128-32. Epub 2007 Dec 10.

[5]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

Chemical & Physical Properties

Boiling Point	624.1ºC at 760 mmHg
Melting Point	222-229.5ºC(lit.)
Molecular Formula	C₂₄H₃₅Cl₂N₃O₄
Molecular Weight	500.458
Exact Mass	499.200470
PSA	74.27000
LogP	3.86080
Appearance of Characters	solid \| off-white
InChIKey	RJNSNFZXAZXOFX-UHFFFAOYSA-N
SMILES	COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1.Cl.Cl
Storage condition	Desiccate at RT
Water Solubility	H2O: 10 mg/mL, soluble

Safety Information

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases	S22-S24/25
RIDADR	NONH for all modes of transport
WGK Germany	3
HS Code	2942000000

Customs

HS Code	2942000000

Articles1

Regulation of Hyaluronan (HA) Metabolism Mediated by HYBID (Hyaluronan-binding Protein Involved in HA Depolymerization, KIAA1199) and HA Synthases in Growth Factor-stimulated Fibroblasts.

J. Biol. Chem. 290 , 30910-23, (2015)

Regulation of hyaluronan (HA) synthesis and degradation is essential to maintenance of extracellular matrix homeostasis. We recently reported that HYBID (HYaluronan-Binding protein Involved in hyaluro...

Synonyms

Ranolazine dihydrochloride

RANOLAZINE HCL

MFCD03788770

RANOLAZINE DI HCL

Ranolazine (dihydrochloride)

N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazinyl}acetamide dihydrochloride

Ranolazine DiHCI

Ranolazine and salt

1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, hydrochloride (1:2)

Ranolazine Dihydrocloride

Ranolazine 2HCl

N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide dihydrochloride

Ranolazine dihydroch

Recommended......